|Ms. Adelene Q. Perkins||Chairman and Chief Exec. Officer||850.97k||N/A||57|
|Dr. Lawrence E. Bloch M.D., J.D.||Pres, Principal Accounting Officer and Treasurer||541.66k||N/A||51|
|Mr. Seth A. Tasker J.D.||VP, Gen. Counsel and Sec.||354.18k||N/A||38|
|Ms. Melissa Hackel||VP of Fin.||N/A||N/A||N/A|
|Dr. Jeffery L. Kutok M.D., Ph.D.||Chief Scientific Officer and Sr. VP||N/A||N/A||50|
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 3; Compensation: 10.